Two weeks ago, I said that one of my favorite stocks right now is Pfizer (PFE). The pharmaceutical giant is in the middle of a transformational period with the goal to return to growth by 2029. It’s navigating through a patent cliff for its blood thinner drug Eliquis and the drop-off of COVID-related revenues. Pfizer […]

The post Mailbag: A Follow-Up on Pfizer & Other Questions appeared first on ETF Trends.